Volume 24 Issue 4
Apr.  2026
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2026  >  24(4): 564-568
LU Gang, LIU Liming, LYU Yunxiang. Predictive value of iSEND immunity scoring system and LIPI on the efficacy of immuno-combination chemotherapy for extensive stage small cell lung cancer treatment[J]. Chinese Journal of General Practice, 2026, 24(4): 564-568. doi: 10.16766/j.cnki.issn.1674-4152.004440
Citation: LU Gang, LIU Liming, LYU Yunxiang. Predictive value of iSEND immunity scoring system and LIPI on the efficacy of immuno-combination chemotherapy for extensive stage small cell lung cancer treatment[J]. Chinese Journal of General Practice, 2026, 24(4): 564-568. doi: 10.16766/j.cnki.issn.1674-4152.004440
shu

Predictive value of iSEND immunity scoring system and LIPI on the efficacy of immuno-combination chemotherapy for extensive stage small cell lung cancer treatment

doi: 10.16766/j.cnki.issn.1674-4152.004440

  • Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 KJ2021A0750

  • Received Date: 2025-03-13
    Abstract
  •   Objective  To analyze the predictive value of iSEND immune score and lung immune prognostic index (LIPI) in the prognosis and efficacy of immunotherapy combined with chemotherapy in patients with extensive-stage small cell lung cancer, and to explore novel indicators guided clinical treatment.  Methods  A retrospective analysis was performed on the clinical data of 127 patients with extensive-stage small cell lung cancer (ES-SCLC) treated with immunotherapy combined with chemotherapy (CIT) admitted to the First Affiliated Hospital of Bengbu Medical University from June 2022 to December 2024. Patients were stratified according to the iSEND immune score and LIPI, respectively, and receiver operating characteristic (ROC) curves were constructed to compare the predictive efficacy of the two scoring systems for treatment response and prognosis. Kaplan-Meier method, univariate and multivariate Cox regression analyses were applied to explore the association between various prognosis-related factors and progression-free survival (PFS).  Results  The median PFS was 3.50 months, 8.50 months, and 13.17 months in the poor, intermediate, and favorable subgroups of the iSEND immune score, respectively; while the median PFS was 3.67 months, 8.20 months, and 10.83 months in the corresponding subgroups of the LIPI, with statistically significant differences (P < 0.001). The area under the curve (AUC) values of LIPI for predicting disease control rate (DCR), objective response rate (ORR), and PFS were 0.731, 0.725, and 0.751, respectively, whereas those of the iSEND immune score were 0.708, 0.649, and 0.677, which were significantly lower than those of LIPI (P < 0.01). Cox regression analysis revealed that lactate dehydrogenase (LDH) and derived neutrophil-to-lymphocyte ratio (dNLR) were independent prognostic factors for PFS in both the entire cohort and all subgroups.  Conclusion  Both scoring systems exhibit favorable predictive value for the prognosis and efficacy of CIT in patients with ES-SCLC, with LIPI demonstrating superior predictive ability. LDH and dNLR, as LIPI components, are independent predictors of PFS across overall and subgroup analyses, likely attributed to LIPI's enhanced predictive capacity over the iSEND model.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    滕熠, 张晓丹, 夏昌发, 等. 中国与全球癌症发病、死亡和患病对比及其预测分析: GLOBOCAN 2022数据解读[J]. 中华肿瘤防治杂志, 2024, 31(23): 1413-1420.

    TENG Y, ZHANG X D, XIA C F, et al. Comparison and predictive analysis of cancer incidence, mortality, prevalence in China and Globally: an interpretation of GLOBOCAN 2022[J]. Chinese Journal of Cancer Prevention and Treatment, 2024, 31(23): 1413-1420.
    [2]
    SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J/OL]. CA Cancer J Clin, 2023, 73(1): 17-48.
    [3]
    KRISTIN A, CHARLES B, AMINI A, et al. American radium society appropriate use criteria on radiation therapy for extensive-stage SCLC[J]. J Thorac Oncol, 2021, 16(1): 54-65. doi: 10.1016/j.jtho.2020.09.013
    [4]
    RUDIN C M, BRAMBILLA E, FAIVRE-FINN C, et al. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3. doi: 10.1038/s41572-020-00235-0
    [5]
    YU H, CHEN P, CAI X, et al. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer[J]. Cancer Immunol Immunother, 2022, 71(3): 637-644. doi: 10.1007/s00262-021-03017-z
    [6]
    张婷素, 袁春樱, 邱海江, 等. 血清特异性烯醇化酶、胃泌素释放肽前体在小细胞肺癌诊断和治疗效果评价中的作用[J]. 中华全科医学, 2019, 17(6): 959-961, 965. doi: 10.16766/j.cnki.issn.1674-4152.000835

    ZHANG T S, YUAN C Y, QIU H J, et al. The role of serum NSE and ProGRP in the diagnosis and treatment evaluation of small cell lung cancer[J]. Chinese Journal of General Practice, 2019, 17(6): 959-961, 965. doi: 10.16766/j.cnki.issn.1674-4152.000835
    [7]
    PARK W, MEZQUITA L, OKABE N, et al. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer[J]. Br J Cancer, 2020, 122(3): 340-347. doi: 10.1038/s41416-019-0643-y
    [8]
    ALDEA M, BENITEZ J C, MEZQUITA L. The lung immune prognostic index (lipi) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients[J]. Transl Lung Cancer Res, 2020, 9(4): 967. doi: 10.21037/tlcr.2020.04.14
    [9]
    CARRIL-AJURIA L, LAVAUD P, DALBAN C, et al. Validation of the lung immune prognostic index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma[J]. Eur J Cancer, 2024, 204: 114048. DOI: 10.1016/j.ejca.2024.114048.
    [10]
    SANDER M S, STUKALIN I, VALLERAND I A, et al. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors[J]. Cancer Med, 2021, 10(8): 2618. DOI: 10.1002/cam4.3784.
    [11]
    HE M, CHI X, SHI X, et al. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy[J]. Thorac Cancer, 2021, 12(23): 3101-3109. doi: 10.1111/1759-7714.13581
    [12]
    李莉, 郝玮, 卢元丽, 等. 广泛期小细胞肺癌免疫检查点抑制剂联合化疗治疗后无进展生存期的影响因素分析[J]. 中国医刊, 2024, 59(8): 899-902.

    LI L, HAO W, LU Y L, et al. Analysis of factors influencing progression-free survival in patients with extensive-stage small cell lung cancer treated with immune checkpoint inhibitors combined with chemotherapy[J]. Chinese Medical Journal, 2024, 59(8): 899-902.
    [13]
    WANG H, SHAN D, DONG Y, et al. Correlation analysis of serum cystatin C, uric acid and lactate dehydrogenase levels before chemotherapy on the prognosis of small-cell lung cancer[J]. Oncol Lett, 2021, 21(1): 73.
    [14]
    马庆功, 邱慧, 王岩, 等. LIPI评分评估局限期小细胞肺癌患者预后的临床价值[J]. 医学研究杂志, 2022, 51(8): 150-154, 159.

    MA Q G, QIU H, WANG Y, et al. Clinical value of LIPI score in evaluating the prognosis of patients with limited-stage small cell lung cancer[J]. Journal of Medical Research, 2022, 51(8): 150-154, 159.
    [15]
    罗怡颖, 王新娟, 王一博, 等. LIPI及iSEND免疫评分在晚期非小细胞肺癌免疫治疗中的预测价值分析[J]. 中国肺癌杂志, 2022, 25(11): 803-810.

    LUO Y Y, WANG X J, WANG Y B, et al. Predictive value of LIPI and iSEND immune scoring system in immunotherapy of advanced non-small cell lung cancer[J]. Chinese Journal of Lung Cancer, 2022, 25(11): 803-810.
    [16]
    WANG Y, MATHAI J, ALAMGEER M, et al. Real-World analysis of clinical characteristics and survival outcomes in patients with extensive-stage SCLC treated with first-line chemoimmunotherapy[J]. JTO Clin Res Rep, 2023, 4(8): 100544. DOI: 10.1016/j.jtocrr.2023.100544.
    [17]
    REBUZZI S E, SIGNORI A, BANNA G L, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)[J]. Ther Adv Med Oncol, 2021, 13: 17588359211019642. DOI: 10.1177/17588359211019642.
    [18]
    GALVANO A, PERI M, GUARINI A A, et al. Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score[J]. Ther Adv Med Oncol, 2020, 12: 1758835920942378. DOI: 10.1177/1758835920942378.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (12) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return